Lower expense ratio (0.08%), higher dividend yield (1.2%), broader diversification with 365 holdings, lower volatility (17.7% max drawdown), and larger AUM ($3.3B) make it suitable for risk-averse investors seeking stable healthcare exposure.
Recommended as the better buy due to significantly lower expense ratio (0.08% vs 0.37%), broader diversification with 338 holdings reducing individual stock risk, and real portfolio diversity with top 5 holdings under 4% each (except largest at 13%)
FHLC is explicitly recommended as the superior choice due to its lower expense ratio (0.08%), broader portfolio of 334 holdings, and consistent outperformance over 1, 3, 5, and 10-year periods compared to its competitor.
FHLC offers broader diversification with 365 holdings and slightly outperformed XLV over 10 years (10.0% vs 9.9% CAGR), but has lower dividend yield, smaller AUM, and shorter track record. Suitable for investors seeking exposure beyond mega-cap stocks.
Recommended for conservative investors due to lower expense ratio (0.08%), higher dividend yield (1.3%), broader diversification (338 stocks), lower maximum drawdown (17.7%), and more stable 5-year returns (~$1,289 on $1,000 invested).
Recommended as the better buy due to significantly lower expense ratio (0.08% vs 0.40%), superior 5-year annualized returns (10.6% vs 8.7%), and cost leadership that benefits long-term investors despite lacking international exposure.
Articles that tag FHLC but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology